In order to facilitate the infiltration of immune cells into the TME of solid tumor, Cure Genetics equips the NKT cells with strong immune infiltration ability through its proprietary technology platforms.
AAV screening platform-VELP™（Vector Engineering Library Production）
VELP™ platform generates high-quality unbiased AAV capsid plasmid library and minimizes the cross-package of viral library production. The VELP™ AAV libraries are well-balanced and with high genotype-phenotype correlation. The good quality of starting library in directed evolution generates more reliable AAV serotype candidates with organ-specific tropism and excellent safety profile, which will significantly accelerate the development of AAV-based genetic therapies.
Optimized CRISPR-Cas gene editing technology by rational design has been applied in developing cell-based therapies.
